Dr. Awan Discusses Combinations With Ibrutinib in CLL
In Partnership With:
Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses combinations with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.
Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses combinations with ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).
Combinations with ibrutinib have shown to be effective, but have not been proven to be superior to ibrutinib alone, says Awan.
The ALLIANCE trial compared ibrutinib to ibrutinib plus rituximab and chemoimmunotherapy, results of which could clarify the argument of monotherapy versus combination.
Related Videos
Related Content
